Trial reportBJU international2014
Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial.
Trial report in BJU international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 93 citations in OpenAlex.
- Early-Onset Prostate Cancer: Epidemiology, Risk Factors, Biology, Clinical Features, Management, and Early Detection.MedComm · 2026Review
- Transperineal (TP) Versus Transrectal (TR) Prostate Biopsy: Efficacy, Safety, and Systemic Challenges-A Narrative Review.Journal of clinical medicine · 2026Review
- Integrating DNA methylation and clinical features to predict prostate cancer prognosis.BMC cancer · 2026Article
- Evaluation of the diagnostic value of three YiDiXie tests in prostate cancer: an observational prospective single-center study.Scientific reports · 2026Observational
- Transperineal Versus Transrectal Prostate Biopsy: A Systematic Review and Meta-analysis of Randomized Controlled Trials Across Settings With and Without Magnetic Resonance Imaging Targeting.European urology open science · 2026Review
- Performance of Retrieval-Augmented Generation Large Language Models in Guideline-Concordant Prostate-Specific Antigen Testing: Comparative Study With Junior Clinicians.Journal of medical Internet research · 2025Article
- Integrating PSA Change with PSA Density Enhances Diagnostic Accuracy and Helps Avoid Unnecessary Prostate Biopsies.Diagnostics (Basel, Switzerland) · 2025Article
- Choosing the path: insights into transperinealTranslational andrology and urology · 2025Article
- Evaluation of the diagnostic value of a three-miRNA panel in prostate cancer: a discovery and validation study.Discover oncology · 2025Article
- Comparison of two analgesia applied to periprostatic nerve blockage during transrectal ultrasound guided prostate biopsy.Northern clinics of Istanbul · 2025Article
- Is prostatic adenocarcinoma detectable by urine cytology-A multicenter retrospective review.The Prostate · 2025Article
- Ultrasound-mediated drug-free theranostics for treatment of prostate cancer.Bioactive materials · 2024Article
- Applications of Urinary Extracellular Vesicles in the Diagnosis and Active Surveillance of Prostate Cancer.Cancers · 2024Review
- Prostate cancer screening in African American men: a review of the evidence.Journal of the National Cancer Institute · 2024Review
- Accuracy of combined multi-parametric MRI and PSMA PET-CT in diagnosing localized prostate cancer: newer horizons for a biopsy-free pathway.European journal of hybrid imaging · 2023Article
- Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations.Nature reviews. Urology · 2023Review
- Comparisons of the diagnostic accuracy across prostate health index, prostate health index density, and percentage free prostate-specific antigen for clinically significant prostate cancer: a prospective diagnostic study.Translational andrology and urology · 2023Article
- Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Cancer Antigen 125, Prostate-Specific Antigen and Other Cancer Markers: A Primer on Commonly Used Cancer Markers.World journal of oncology · 2023Review
- Initial experience and cancer detection rates of office-based transperineal magnetic resonance imaging-ultrasound fusion prostate biopsy under local anesthesia.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Article
- Association of Warmer Weather and Infectious Complications Following Transrectal Ultrasound-Guided Prostate Biopsy.Journal of personalized medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo examine mortality and morbidity after prostate biopsy in the intervention arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial. SUBJECTS AND
methodsAbstractors from the PLCO trial recorded the types and dates of diagnostic follow-up procedures after positive screens and documented the types and dates of resultant complications. Cancers and deaths among the participants were tracked. The mortality rate in the 120-day period after prostate biopsy was compared with a control rate of deaths in the 120-day period after a negative screen in men without biopsy. Multivariate analysis was performed to control for potential confounders, including age, comorbidities and smoking. Rates of any complication, infectious and non-infectious complications were computed among men with a negative biopsy. Multivariate analysis was used to examine the risk factors for complications.
resultsOf the 37,345 men enrolled in the PLCO trial (intervention arm), 4861 had at least one biopsy after a positive screen and 28,661 had a negative screen and no biopsy. The 120-day mortality rate after biopsy was 0.95 (per 1000), compared with the control group rate of 1.8; the multivariate relative risk was 0.49 (95% CI: 0.2-1.1). Among 3706 negative biopsies, the rates (per 1000) of any complication, infectious and non-infections complications were 20.2, 7.8 and 13.0, respectively. A history of prostate enlargement or inflammation was significantly associated with higher rates of both infectious (odds ratio [OR] = 3.7) and non-infectious (OR = 2.2) complications. Black race was associated with a higher infectious complications rate (OR = 7.1) and repeat biopsy was associated with lower rates of non-infectious complications (OR = 0.3).
conclusionMortality rates were not found to be higher after prostate biopsy in the PLCO trial and complications were relatively infrequent, with several risk factors identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.